{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:24:15Z","timestamp":1792027455631,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Faricimab, the new anti-vascular endothelial growth factor (VEGF) drug including a bispecific antibody targeting both VEGF-A and angiopoietin-2 (Ang-2), has emerged as a therapeutic option for macular edema secondary to retinal vein occlusion (RVO), and its efficacy has been demonstrated in randomized controlled trials (RCTs); however, reports on its use in clinical practice are still limited. This study was conducted to evaluate the real-world treatment outcomes of faricimab for macular edema secondary to RVO, managed with a single initial injection plus pro re nata (1\u2009+\u2009PRN) approach in both treatment-na\u00efve and previously treated patients who switched to this regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study included patients diagnosed with branch or central RVO, who received intravitreal faricimab therapy following the 1\u2009+\u2009PRN protocol. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty patients (17 na\u00efve and 13 switched) were included. The number of IVF was 1.4\u2009\u00b1\u20090.7 and 2.4\u2009\u00b1\u20092.1, in the na\u00efve and switch groups, respectively. The mean follow-up period was 3.7\u2009\u00b1\u20092.7 and 4.9\u2009\u00b1\u20092.9 months in the na\u00efve and switch patients, respectively. Mean LogMAR BCVA improved in the na\u00efve group from 0.30\u2009\u00b1\u20090.37 at baseline to 0.11\u2009\u00b1\u20090.20 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) at the final visit, while there was no significant difference between 0.45\u2009\u00b1\u20090.45 at baseline and 0.35\u2009\u00b1\u20090.37 at the final visit in the switch group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.19). CMT reduction was significant in both groups; from 442\u2009\u00b1\u2009117\u00a0\u03bcm at baseline to 304\u2009\u00b1\u200957\u00a0\u03bcm at one month after final IVF (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) in the na\u00efve group; and from 436\u2009\u00b1\u2009170\u00a0\u03bcm at baseline to 285\u2009\u00b1\u200976\u00a0\u03bcm at one month after final IVF (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0002) in the switch group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The 1\u2009+\u2009PRN faricimab regimen improves vision and reduces macular edema with a reduced injection burden in patients with RVO. These findings validated the real-world efficacy of faricimab and supported its use as a viable therapeutic agent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00703-3","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:43:08Z","timestamp":1752576188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Short-term real-world effectiveness of faricimab on macular edema due to retinal vein occlusion"],"prefix":"10.1186","volume":"11","author":[{"given":"Toshiaki","family":"Hirakata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Toride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Ashikaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Nochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimune","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"6","key":"703_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","volume":"117","author":"SL Rogers","year":"2010","unstructured":"Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094\u2013101. PubMed PMID: 20430447.","journal-title":"Ophthalmology"},{"key":"703_CR2","doi-asserted-by":"publisher","unstructured":"McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1113-23.e15. PubMed PMID: 20430446. https:\/\/doi.org\/10.1016\/j.ophtha.2010.01.060","DOI":"10.1016\/j.ophtha.2010.01.060"},{"issue":"6","key":"703_CR3","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/s41433-021-01620-z","volume":"36","author":"KL Spooner","year":"2022","unstructured":"Spooner KL, Fraser-Bell S, Hong T, Wong JG, Chang AA. Long-term outcomes of anti-VEGF treatment of retinal vein occlusion. Eye (Lond). 2022;36(6):1194\u2013201. Epub 20210611. https:\/\/doi.org\/10.1038\/s41433-021-01620-z","journal-title":"Eye (Lond)"},{"issue":"5","key":"703_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/jcpt.12551","volume":"42","author":"T Qian","year":"2017","unstructured":"Qian T, Zhao M, Xu X. Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: a meta-analysis. J Clin Pharm Ther. 2017;42(5):519\u201329. Epub 20170622. https:\/\/doi.org\/10.1111\/jcpt.12551","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"703_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10384-023-00985-w","volume":"67","author":"R Mori","year":"2023","unstructured":"Mori R, Honda S, Gomi F, Tsujikawa A, Koizumi H, Ochi H, et al. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Jpn J Ophthalmol. 2023;67(3):301\u201310. Epub 20230411. https:\/\/doi.org\/10.1007\/s10384-023-00985-w","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"703_CR6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","volume":"131","author":"TY Wong","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et al. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024;131(6):708\u201323. Epub 20231228. https:\/\/doi.org\/10.1016\/j.ophtha.2023.12.026","journal-title":"Ophthalmology"},{"issue":"5","key":"703_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10384-024-01078-y","volume":"68","author":"M Shimura","year":"2024","unstructured":"Shimura M, Oh H, Ueda T, Kitano S, Mitamura Y, Sato J, et al. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial. Jpn J Ophthalmol. 2024;68(5):511\u201322. Epub 20240731. https:\/\/doi.org\/10.1007\/s10384-024-01078-y","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"703_CR8","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, et al. Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-Week results from the BALATON and COMINO trials. Ophthalmology. 2024;131(8):950\u201360. Epub 20240126. https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.029","journal-title":"Ophthalmology"},{"issue":"3","key":"703_CR9","doi-asserted-by":"publisher","first-page":"100302","DOI":"10.1016\/j.xops.2023.100302","volume":"3","author":"LO Hattenbach","year":"2023","unstructured":"Hattenbach LO, Abreu F, Arrisi P, Basu K, Danzig CJ, Guymer R, et al. BALATON and COMINO: phase III randomized clinical trials of faricimab for retinal vein occlusion: study design and rationale. Ophthalmol Sci. 2023;3(3):100302. Epub 20230327 PubMed PMID: 37810589; PubMed Central PMCID: PMCPMC10556281. https:\/\/doi.org\/10.1016\/j.xops.2023.100302","journal-title":"Ophthalmol Sci"},{"key":"703_CR10","doi-asserted-by":"publisher","unstructured":"Danzig CJ, Dinah C, Ghanchi F, Hattenbach LO, Khanani AM, Lai TYY, et al. Faricimab treat-and-extend dosing for macular edema due to retinal vein occlusion: 72-Week results from the BALATON and COMINO trials. Ophthalmol retina. 2025. Epub 20250317. PubMed PMID: 40107501. https:\/\/doi.org\/10.1016\/j.oret.2025.03.005","DOI":"10.1016\/j.oret.2025.03.005"},{"issue":"12","key":"703_CR11","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","volume":"105","author":"T Ciulla","year":"2021","unstructured":"Ciulla T, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes. Br J Ophthalmol. 2021;105(12):1696\u2013704. Epub 20201014. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317337","journal-title":"Br J Ophthalmol"},{"key":"703_CR12","doi-asserted-by":"publisher","unstructured":"Hafner M, Herold TR, Kufner A, Asani B, Anschutz A, Eckardt F, et al. Switching to faricimab in therapy-resistant macular edema due to retinal vein occlusion: initial real-world efficacy outcomes. J Clin Med. 2025;14(7). Epub 20250403. https:\/\/doi.org\/10.3390\/jcm14072454","DOI":"10.3390\/jcm14072454"},{"issue":"1","key":"703_CR13","doi-asserted-by":"publisher","first-page":"12068","DOI":"10.1038\/s41598-023-39303-2","volume":"13","author":"YR Chung","year":"2023","unstructured":"Chung YR, Woo TK, Park HR, Lee K. Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion. Sci Rep. 2023;13(1):12068. Epub 20230726. https:\/\/doi.org\/10.1038\/s41598-023-39303-2","journal-title":"Sci Rep"},{"key":"703_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ph15010059","author":"CA Rodriguez-Fernandez","year":"2022","unstructured":"Rodriguez-Fernandez CA, Campo-Gesto A, Lopez-Lopez A, Gayoso-Rey M. Real-world evidence for treat-and-extend regimen of ranibizumab therapy for macular oedema secondary to branch retinal vein occlusion. Pharmaceuticals (Basel). 2022;15(1). Epub 20220103. PubMed PMID: 35056116; PubMed Central PMCID: PMCPMC8778817. https:\/\/doi.org\/10.3390\/ph15010059"},{"key":"703_CR15","doi-asserted-by":"publisher","first-page":"176691","DOI":"10.1016\/j.ejphar.2024.176691","volume":"976","author":"A Kuriyama","year":"2024","unstructured":"Kuriyama A, Nakamura S, Inokuchi Y, Abe H, Yasuda H, Hidaka Y, et al. The protective effect of anti-VEGF-A\/Ang-2 bispecific antibody on retinal vein occlusion model mice. Eur J Pharmacol. 2024;976:176691. Epub 20240529. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176691","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"703_CR16","doi-asserted-by":"publisher","first-page":"e0323088","DOI":"10.1371\/journal.pone.0323088","volume":"20","author":"T Hirakata","year":"2025","unstructured":"Hirakata T, Hara F, Nochi Y, Shinohara D, Yamamoto S, Hiratsuka Y, et al. Short-term real-world outcomes of diabetic macular edema treated with intravitreal faricimab. PLoS ONE. 2025;20(5):e0323088. Epub 20250513. https:\/\/doi.org\/10.1371\/journal.pone.0323088","journal-title":"PLoS ONE"},{"issue":"18","key":"703_CR17","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD, et al. Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye (Lond). 2024;38(18):3569\u201377. Epub 20241011. https:\/\/doi.org\/10.1038\/s41433-024-03364-y","journal-title":"Eye (Lond)"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00703-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00703-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:24:53Z","timestamp":1757247893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-025-00703-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00703-3","relation":{"references":[{"id-type":"doi","id":"10.3390\/ph15010059","asserted-by":"subject"}]},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Institutional Review Board of Juntendo University (16\u2013292). Written informed consent from the patients enrolled in this study was waived, based on the opt-out method facilitated by our hospital bulletin board. All patient data were anonymized and retrospectively collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}